Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated Ras pathway, one of the most common family of genetic defects leading to cancer.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-28.76M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -2185.97% |
| Return on Assets (Trailing 12 Months) | -442.99% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.35 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.35 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.05 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.08 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.30 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.34 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 127.51M |
| Free Float | 127.38M |
| Market Capitalization | $106.88M |
| Average Volume (Last 20 Days) | 0.63M |
| Beta (Past 60 Months) | 1.14 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 6.82% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |